27
Participants
Start Date
March 31, 2003
Primary Completion Date
October 31, 2005
Study Completion Date
June 30, 2008
Campath-1H
Participant will receive three test doses of Campath-1H (3, 10, and 30mg). If this is tolerated then they will receive Campath-IH three times a week for 6 weeks.
Beth Isreal Deaconness Medical Center, Boston
Dana-farber Cancer Insitiute, Boston
Massachusetts General Hospital, Boston
Collaborators (1)
Brigham and Women's Hospital
OTHER
Beth Israel Deaconess Medical Center
OTHER
Massachusetts General Hospital
OTHER
Bayer
INDUSTRY
University of California, Los Angeles
OTHER
Northwestern University
OTHER
Arizona Oncology Associates
NETWORK
Dana-Farber Cancer Institute
OTHER